Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sneha Annie Sebastian1,2, Inderbir Padda3, Eric J Lehr4
1Department of Internal Medicine, Azeezia Medical College, Kollam, Kerala, India. snehaann1991@gmail.com.
Summary
Aficamten, a novel cardiac myosin inhibitor, effectively reduces left ventricular outflow tract gradients and improves heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). This treatment shows sustained efficacy and a favorable safety profile in long-term studies.
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Obstructive hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease characterized by abnormal thickening of the heart muscle, leading to left ventricular outflow tract (LVOT) obstruction and heart failure symptoms.
- Current treatments like beta-blockers, calcium channel blockers, and disopyramide offer symptomatic relief but do not directly address the underlying hypercontractility in obstructive HCM.
- Aficamten represents a new class of therapeutics, cardiac myosin inhibitors, designed to target the molecular basis of HCM by reducing cardiac muscle hypercontractility.
Purpose of the Study:
- To evaluate the long-term clinical efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM).
- To explore the molecular mechanisms of sarcomere-targeted therapy in reducing LVOT gradients.
- To discuss the potential of aficamten as a preferred treatment option compared to existing therapies and other myosin inhibitors.
Main Methods:
- Analysis of data from the REDWOOD-HCM open-label extension (OLE) study and other ongoing clinical trials.
- Assessment of changes in resting and Valsalva left ventricular outflow tract (LVOT) gradients.
- Evaluation of heart failure symptom improvement and safety profiles, including adverse events and drug-drug interactions.
Main Results:
- Aficamten significantly reduced resting and Valsalva LVOT gradients within two weeks of treatment initiation.
- Sustained improvements in LVOT gradients were observed up to 48 weeks in patients receiving aficamten.
- Aficamten demonstrated a favorable safety profile and was associated with improvements in heart failure symptoms.
Conclusions:
- Aficamten is a safe and effective treatment for reducing LVOT gradients and improving symptoms in obstructive HCM.
- Its shorter half-life and reduced potential for drug-drug interactions make it a potentially preferable option compared to mavacamten.
- Sarcomere-targeted therapy with aficamten offers a promising approach for managing obstructive HCM by addressing the underlying pathophysiology.
More Related Videos
07:02Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
6.4K
08:42Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
3.5K
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463